Refractory immune thrombocytopenia treated with low-dose decitabine combined with recombinant human thrombopoietin or eltrombopag: Two case reports.

• Tác giả: Minxia He, Huifang Jiang, Yuxia Jiang, Haiying Wu, Xiaofeng Xu, Yani Xu
• Ngôn ngữ: eng
• Ký hiệu phân loại: 324.27104 Political parties
• Thông tin xuất bản: United States : Medicine , 2025
• Bộ sưu tập: NCBI
• ID: 15156

Tóm tắt

RATIONALE: Immune thrombocytopenia (ITP) is an autoimmune-mediated disorder caused by antibody-mediated platelet destruction and impaired platelet production by megakaryocytes. Treating refractory ITP remains a significant challenge. PATIENT CONCERNS AND DIAGNOSES: We report 2 patients with refractory ITP. INTERVENTIONS AND OUTCOMES: Two patients received low-dose decitabine combined with recombinant human thrombopoietin or eltrombopag. Platelet counts in both patients increased to within the normal range. LESSONS: Low-dose decitabine combined with recombinant human thrombopoietin or eltrombopag may exert a synergistic effect in the treatment of refractory ITP.